Alemtuzumab in the treatment of multiple sclerosis
Óscar Fernandez Institute of Clinical Neuroscience, Neurology Department, Hospital Regional Universitario Carlos Haya, FIMABIS, Malaga, Spain Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-remit...
Saved in:
Main Author: | Fernandez Ó (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alemtuzumab for the treatment of multiple sclerosis
by: Willis MD, et al.
Published: (2015) -
Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis
by: Tereza Gabelić, et al.
Published: (2021) -
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
by: Dörr J, et al.
Published: (2016) -
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017) -
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
by: Havrdova E, et al.
Published: (2017)